Seasonal affective d isorder (SAD) and phototherapy ha ve recentl y been th e su bject of a great dea l of interest in the psychiatri c literature. First d escribed in 1984 (I), SA D is now defined as " a cyclic illn ess c ha rac te r ized by recurre n t episodes of fal l/winter depression alternating with periods o f spring/summ e r euthymia (no r ma l mood) or hypomania (mild elation and beha vioral ac t iva tion)" (2) . Rece n t findings indicate that th ere ma y be at least two additi onal patterns of seasonal d e p ressio ns, one characterized by annual summer depressions with euthyrnic, hypomanic or manic symptoms in the winter, and th e other characterize d by depressive episodes occurring in both winter and summer (3) (4) (5) (6) .
As defined b y Rose n thal e t al. (3) , SAD d iagnostic cr ite r ia include :
I) a hi story of at least one major depressive e p isode, according to RD C (7) criteria; 2) regu larly occurring fall-winter depressions (a t least two oc currin g during consecutive winters) alternating with nondepressed pe r iod s during spring and summer; 3) no other major psychiatric disorders; and, 4) no psychosoc ial variables acco u n t in g for the regular cha nges in mood .
SAD has ga ined increased acceptance with the inclusion of " seasonal pattern" criteria for a n umber of different diagnoses within th e Mood Disorder section of DSM lll-R (8) .
Recently a n umber of reports of additiona l "seaso na l" diagnostic e nt ities have appeared in the scientific literature, including, " reverse seaso na l a ffec tive disorder" (3), "seasonal affective disorder in ch ild re n and ad ol escents" (9) , "seasonal premenstrual syndrom e" ( 10), seasonal battering of wom en ( I I) a nd a h ypothesized seasona l obesity di sorder (12) . Furthermore , th e lay press has reported extensivel y on SAD and phototherapy (13) (14) (15) (16) (17) (18) (19) , with photothe rap y currentl y being touted as potentially beneficial for d epression , multiple sclerosis, A IDS, premenstrua l syndrome, school absenteei sm , low work product ivit y, poor morale , j e t lag , a nd denta l cavities (13) (14) (15) (16) (17) (18) (19) (20) .
Whi le others h a ve written to express concern about th e validity of th ese diagnoses and there proposed etiologies (21 -23) , the validity o f th e di agnosis of SAD is the focus of this paper.
LITERAT URE SUP PORT FOR SAD
Although numerous papers have been published o ve r th e yea rs th a t support the existence of seasonal differences in psychiatri c disorde rs (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) , 41 many of these early papers do not seem readily applicable to support cu r rent notions of the entity of SAD . Although, Rosentha l et al. briefly allude to t he numerous discrepancies in these early studies (40), Christensen et al. in th e "Myths of Mid-Winter Depression," present a detailed literature r e view of t he conflicting nature of the empirical data that relates to se aso na l peaks of psychiatric disorders (41) . On closer review many of these seaso nal st udy populations do not appear to relate to the current populations being described as having the SAD diagnosis. For example, the early research was don e almost exclusively with psychiatric inpatients and with few exceptions (42), SAD is described as a mi ld disorder found primarily in outpatient populations (1-3,43-45). Many of the early studies did not differentiate the specific "s easonal " diagnoses, or if diagnoses were provided, they did not discuss th e specific symptomatology. In addition, although not specifically stated , one must assume from the current clinical descriptions of SAD that most patients do not di spl ay suicidal thoughts or suicidal behavior, therefore, excluding many of th e subject populations reported on in the papers on seasonality of suicides.
A related issue is the lack of current epidemiologic evidence fo r SAD and the absence of literature support for determining its reliability, validity or prevalence as a psychiatric diagnosis. The patient population upon whi ch the SAD diagnosis was developed was a partly self-selected research population at NIMH, which was included in what appears to be a non-controlled phototherapy trial (I). Unfortunately, the majority of the follow-up studies, by NIMH a nd other groups, have used this same method of subject selection to d evelop th ei r study populations, to test the effects of phototherapy and to establish th ei r demographic data . An exception to this approach was a recent co m pa r iso n of seasonal and nonseasonal affective disorders (46) . This study used a psychiatry clinic population as its source of subjects, did not incorporate a phototherap y protocol, and used a control population to test their h ypothesis. They repo rted a "prevalence of seasonal depression" of 38 % in their study population (46 ) , whereas the most frequently quoted prevalence estimate for SAD ha s bee n "about 4-5 % of manic-depressive patients" (47) . Unfortunately, Garve y et al. use their own idiosyncratic criteria to diagnosis SAD (46) . In fa ct, this type of diagnostic variance is a common problem throughout the SAD literature . The significance of this variability in describing psychiatric syndromes has bee n discussed by Spitzer (49) . He stated that "criterion variance " o ccurs wh en th e re are differences in the criteria that are used to make a certain diagnosi s and this is one of the major sources of difficulty with reliability in psychiatric diagn oses.
POOR RELIABILITY DUE TO CRITERION VARIANCE
Development of diagnostic criteria would provide a means to ve rify reliability of SAD as a diagnosis and possibly establish its d escriptive val id ity. However, while most researchers have attempted to describe the di agnosis of SAD based on the Research Diagnostic Criteria (RDC) for major depression (7), there is a recurring problem with various authors changing th e SA D cr ite ria they report in their individual studies. While Rosenthal e t al. h ave report ed th at other researchers have used similar criteria (3), a review shows th a t the current SAD criteria differ significantly from those initially presented in 1984 (1) and those presented by other groups (2, 47, 48) . Sometimes the cha nge s are qui te extensive, such as, diagnosing SAD without a major affective di agnosis as a cr ite r ia (47) , leaving out criteria pertaining to ps ychosocial influences (1), or not ruling out other psychiatric disorders (48) . Therefore, failure to specifica lly define how these individuals are being diagnosed could decrease the reliab ility of SAD . Perhaps this accounts for Yerevan ian et al. reporting that SAD pat ie n ts usuall y have unipolar disorder (50), Rosenthal et al. reporting that SAD pati e nt s usually have bipolar disorder (1,3), and Wirz-J ustice et al. reporting that SAD patients usually give a history consistent with bipolar disorder , but actuall y fai l to show an y evidence of mania or h ypomania on longitudinal fo llo w-up in to the spring/summer (47) .
ETIOLOGIC HYPOTHESES
Rosenthal and Fishman (51) recently revi ewed current th eories of the reported antidepressant effect of light on SAD patients and di scu ssed fo ur: THE MELATONI THEORY: Melatonin is se creted in a circadian pattern with nocturnal release from the pineal gland in response to e n vironmental light input to the retinas. The pathway of information flow is reported as ; light input to the retinas is passed along the retino-h ypothalamic tract to the suprachiasmatic nuclei of the hypothalamus, which in turn st im u lates the specific pattern of melatonin release from the pineal gland. In SAD it is postulated that "the symptoms of SAD are due to an abnormality in mela to ni n secretion or, perhaps, an abnormal brain response to melatonin" (5 1). While not being totally excluded, this theory se ems less plausible now that report d ata indicates that melatonin suppression is not necessary to dem onstrate beneficial effects of light treatment (48) .
THE PHASE-SHIFT HYPOTHESIS: A theory dis cu ssed by nume rous authors (51) (52) (53) (54) (55) (56) , who postulate that "light corrects an abnorm ality of circad ian phase either relative to real clock time or internall y (between different circad ian rhythms)" (51) . These authors have also speculated that exposure to light in th e morning brings the SAD patient's rhythms back to normal , thus stabilizing their mood. Conversely they suggest that phototherapy in the e ve n ings should d ela y circadian rh ythms, thus exacerbating the patient's symptoms. The mo st important arguments against this theory are the more recent reports th at the tim e of day of phototherapy application does not alter th e antidepressant e ffec t of phototherapy (9, 48, 57) .
THE DIRECT PHOTO-CHEMICAL HYPOTHESIS: This is a general theory that postulates an abnormality existing in the brain , perhaps in th e hypothalamus, that is probably genetic and which produces the sym p to ms of SAD in the absence of su fficie n t light. Phototherapy fun cti ons by reversing this brain deficiency (51) . THE PLACEBO THEORY: A major co ncern with all of the SAD lite rature lies in the difficulty of controlling for placebo and p ositi ve expectancy effects. This is particularly important because most of th e literature that bears on the biologic theories seems to a rgue b y inference that response to photo th e rapy treatment constitutes reasonable evidence of the validity of th e SAD diagnosis (1-5,47 ,52 ). Further, a number of SAD papers d o not consider the placebo effect at all (3-5 ,42,55), while papers that d o , p r o vid e a one-sided argument against it (1-2 ,44-45 ,47-48 ,51,5 3,58).
Proponents of SAD and light treatment ac cept th at th e consistent two-to four-da y time lag for improvement with phototherapy a nd the likel ih o od of relapse occurring over a similar tim e spa n whe n the lights a re wit hdrawn mitigate against th e placebo hypothesis. Also, SAD research ers re port that the beneficial effects of phototherapy persist throughout th e t reat ment co urse and reliably return with subsequent treatments during r elapses. Furthe rmo re , a fair degree of consistent findings in phototherapy responses from year to year and between different in vestigative groups (1 ,47 ,59) ha s been cla im ed , as well as a dose-response relationship. To bolster argum ents agains t th e placeb o theory, proponents also cit e the evidence o f a circad ian rh ythm in response se nsi tivity to treatment (i.e . " so me stud ies have shown a great er efficacy of light t reatment in the morning than in the evening") (6 1-6 2). Additionall y, SA D p r o po ne nt s invoke the notions about light's multiple biological e ffects (6 1-68) and the superiority of light therapy co m pa red to sham light co n trol treatments (1 ,47 ,53,69,70) as evidence to refute the placebo effect.
However, accumulating evidence seems to refute a number of these arguments: In regard to the reported co nsiste n t time lag until sym p tom relapse when lights are withdrawn, at least one group rep o rts th at sym ptom relapse is not co ns iste nt and ma y oc cur within o ne da y of th e withdra wal of ligh ts or not occu r a t a ll (4 7). Al so , recent data suggests that a circad ia n sensiti vity to response to timing o f phototherapy is not present, as the timing o f th e pho toth e rap y is not critical for producing th e a n t idep ressa n t effect (i.e . applicati ons a t var ious times throughout the da y and e ve n in g have resulted in b enefi cial effec ts) (48, 57, (69) (70) .
The theory behind dim (250-300 lux) light as a co ntrol vers us brig h t (2,500 lux) light as the active treatment was initiall y based on th e findin g th a t at 500 lux, light suppresses production of melatonin in normal vo lu n teers (61) . Howev er, a subsequent st ud y demonstrated that the suppression of mel a ton in is not necessary for phototherapy to produce its antidepressant effec t in SA D patients (48) . This finding casts d oubt not onl y o n the melatonin hypo th esis, but a lso on the use of dim light as a " no nac t ive" co ntro l and bright ligh t as an " ac t ive " treatment. Wehr et al. have reported th at dim "control" ligh ts have repeatedl y not shown sign ifica n t antidepressant e ffects (48) a nd tha t other studies have confirmed these findings (47 ,59) . Howev er, a review of the other studies they reference reveals that Wirz-Justice e t aI. , reports antidepressant effects with dim light, at levels as low as 250 lux , in 8 3% of th e ir SAD population (47 ,71) . One of the other papers, b y Hellekson et aI., was a non-co ntro lled treatment trial of six SAD patients that used onl y bright light (2500 lu x) (59) . Furthermore, Wirz-J ustice et al. (47) note that 30 to 40 % of SA 0 pat ien ts in previous phototherapy trials have responded to dim light ( 1,57,58). T hese authors sp ecu la te that with th e sma ll number o f su bjects in a ll of t hese SAD studies, such differences in response may be related to the se lec t io n cr iteria (47) . Doubts are further increased by reports that, in addition to less light in tensity , antidepressant responses are seen with less time of e xp os ure to ph oto th erap y (9 ,47) .
SAD advocates note that " pa t ie n ts become d epressed in a regular and predictable way" (3), ye t almost 40 % of Rosenthal e t al. 's in itial group of SAD patients failed to develop an y evidence of d epression wh en foll owed d uring th e fal l/winter of 1984 (1). Further Ros enthal e t a l. report th at > 90% of SAD patients have a bipolar di sorder (3), yet two o t her g roups h ave reported th a t non e of th eir SAD patients di spl a yed e vid e nce o f man ia o r h ypoma nia on foll ow up (4 7 ,50). Furthermore , whil e "winter depression " is the term that is used with the diagnosis, th e actual onset of th e reported d epressions ca n occu r a nyti me between July and January (5).
Additional arguments for light being a n " ac tive" agent, a nd not a p lacebo effect were presented by Wirz-Justice e t al. (4 7). The a ut hors stated th a t placebo e ffec ts are more ev iden t in mild or neurotic depressions a nd report that th eir SAD patients were severely d epressed. This argument is problemat ic for two reasons: First, th ere is little empirical e vid e nce to support this assertion because placebo reactions are commonly demonstrat ed in norm al , neu r oti c and psych o t ic indi viduals (62 ) . Se cond, as stated before most SAD patients a re reported to have "mild" depressions (1-2 ,4 3-45). Further, the y argu e th at th e "use of lights under self-selected conditions led to repeated improv em ent in th e sam e individual." While we would agree this probabl y suggests th e individual is deriving so me type of benefit from phototherapy, it is n ot clear if it serves to diffe rentiate " active" from "placebo " origins o f that benefit, particularly in light of th e reports of co nd itio ned placebo effec ts (72) (73) . Lastl y, they assert that "relapse after withdrawal is considered a criterion for a n active agent." The authors did not provide a reference for this statement, howev er th ere are reports that individuals have displayed several yea rs of ch ro n ic d ependence with withdrawal sym p to ms on placebo al one (74) . Further, dru g withdrawal symptom s may occur as a psychologically co nd it io ned responses, rath e r tha n as biologically induced sym p tom s (72-7 3) .
The placebo effect has been th e subject of extensive research and the re is little doubt that it occurs in both experimental and clinical stu d ies (75) . So me of the findings about placebo responses that are appli cable to the cur rent discus-J EFF ERSO N JO UR N A L OF PSYCHIATRY sion o f SAD include: A positive th erapeutic resp onse of almost 10 0 % has be en reported with placebo a lo ne (72) (73) (74) (75) , this co u ld accou n t for the 80 % positive response rate most fr equentl y reported for phototherapy (3) . In addition, the most fr equently cite d sym p to ms associated with the placebo reaction a re " dep ressio n , anxiety and e motio nality" (75) , whereas Rose nthal et al. report th e three affects associated with SA D a re "sad ness, a nx ie ty a nd irritability." Nausea , h eadach es, and nervousn ess are side e ffec ts th at a re freq uentl y seen with placebos (75) . Wirz-] usti ce e t al. report phototherapy side effects consist o f nausea, headach es, " hy po ma n ic ac tiva tio n ," a nd /or irritabili ty (42) .
Experimenter bias e xp la ins why uncontrolled stu d ies report success more frequ entl y than co ntro lle d stud ies (7 5) . While it has bee n demonstra ted that th e transfer o f research er bias to patients can occu r sub t le ty (75) , in th e phototherapy trials written presentation of th e research ers' SA D t heories and past " successfu l" use o f light treatments are used as pre-conditions for subject selection (1, 9,44,45,49 ,59) .
DISCUSSIO N
We hav e been unabl e to find an y clinical , d emogra ph ic, fami ly histor y, laboratory stu dy, o r co ntro lled light th erapy research th a t h as va lidated SAD as a distinct synd rome. Yet d espite th is lack of support we now see a Aurry of additional "seasonal" di agn osti c e n t ities a p peari ng in t he scientific literature (3,9-12, 2 0) and the la y press ( 13-19) . One must quest ion whether seasonal variation in mood is a characte r istic found in t he general pop ula t io n , including psychiatric patients ge nera lly, or if th ere is actua lly a d ist inct subgroup with ex treme seasona l differences in psyc hia tric sym p toms .
Furthermore, if SAD represents some typ e o f specific b iol og ic mechanism , sim ilar to hibernation in a n ima ls (3), wh y is th e re so much variabilit y in the onset, presentation , and response to treatment? T hese di ffe rences occur within indi vidual patients and wh en co m pa r ing different SA D pa t ients.
As recently pointed o ut by Winokur e t aI., " ma king up ne w sets of diagnostic cr ite r ia in Am erican psychiatry has beco me a cottage industr y with little attempt at quality co ntro l" (76) . The hi st ory of psychiat r y a nd med icin e is marked with clinicians a nd resea rchers a like e m bracing ne w di sord ers and uncontrolled treatments, whi ch for a while, se em to provide dram a tic progress. Only after fu rth e r clinical e xpe r ie nce and judicious application of the scientific method, do these breakthroughs assume a more modest position in th e unde rsta nd in g of psychiatric di sorders and their treatments. A lt hough face va lidity ma y b e th e fir st step toward id enti fying a psychiatric di sorder (77), we must be a b le to es ta b lish more powerful ty pes of diagnostic va lidi ty , such as d escr ip t ive a n d predicti ve validity. Only if suc h co nd itio ns ca n be met can we justify presenting SAD as a di stinct behavioral syn drome, rather tha n a random co llec t io n of clinical features com mo n ly seen in indi vidual s with other types of mental disorders a nd in individuals wit hou t mental di sorders.
